Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mount Sinai School of Medicine launches a phase II clinical trial for new gene transfer drug study

03.02.2006


As many as 8-10 million Americans have Peripheral Artery Disease (PAD), by age 70, roughly 20 percent of the population has it, and people with PAD face a six-to-seven times higher risk of heart attack or stroke.



PAD, commonly seen in patients with a history of smoking, diabetes, and/or coronary artery disease, is the build up of fatty deposits in the inner linings of the artery walls of the heart and brain. These blockages restrict blood circulation, mainly in arteries leading to the kidneys, stomach, arms, legs and feet. In its early stages a common symptom is uncomfortable cramping or fatigue in the legs brought on by walking and relieved with rest--a condition called intermittent claudication.

The WALK study, led by the Mount Sinai School of Medicine and sponsored by Genzyme Corporation, will determine if a new gene transfer treatment, Ad2/HIF-1a/VP16, helps ease the pain caused by intermittent claudication.


"The leg pain experienced by people with PAD is very different than leg pain caused by joint problems or arthritis," said Dr. Jeffrey W. Olin, the Principal Investigator for the WALK study and Professor of Medicine at the Mount Sinai School of Medicine and Director of Vascular Medicine and the Vascular Diagnostic Laboratory in the Zena and Michael A. Wiener Cardiovascular Institute of The Mount Sinai Medical Center. "This gene transfer treatment could offer new hope for the millions of people that suffer from the leg pain associated with peripheral arterial disease."

HIF-1a (Hypoxia-inducible factor-one alpha gene) is produced naturally in the body when there is not enough oxygen reaching the leg tissue. The study drug, Ad2/HIF-1a/VP16, is very similar to the HIF-1a the body naturally produces but has been genetically changed to include important biological characteristics that may grow new blood vessels and improve blood flow in legs.

Mount Sinai and 40 other sites involved in the trial are seeking to enroll approximately 300 men and women in the United States and Europe. The study is open to male or female patients between the ages of 40-80 who suffer from PAD that has progressed to activity-limiting discomfort in at least one leg. The study will assess the safety and effectiveness of three different doses of Ad2/HIF-1a/VP16 compared to placebo in treatment of intermittent claudication.

A Phase I study was conducted using Ad2/HIF-1a/VP16 in patients with Critical Limb Ischemia and preliminary safety and potential bioactivity were demonstrated. Regulatory authorities in both the United States and Europe have reviewed this protocol and authorized Genzyme to proceed with enrollment.

If you are interested in participating, please call (212) 241-8902 or visit www.walkstudy.com.

Cardiovascular Research At Mount Sinai

The Zena and Michael A. Wiener Cardiovascular Institute and the Marie-Josée and Henry R. Kravis Center for Cardiovascular Health at The Mount Sinai Medical Center are preeminent resources for the study and treatment of heart and blood vessel diseases. Committed to finding new and improved methods of diagnosis, treatment and prevention, they comprise a multidisciplinary effort that brings together the extraordinary expertise of Mount Sinai School of Medicine and The Mount Sinai Hospital in cardiovascular medicine, cardiovascular surgery, medical education, research and community service, with state-of-the-art facilities for patient care, advanced laboratories for scientific research and leading programs for postgraduate education of clinician-scientists.

Mount Sinai School of Medicine

Located in Manhattan, Mount Sinai School of Medicine is internationally recognized for ground-breaking clinical and basic-science research, and innovative approaches to medical education. Through the Mount Sinai Graduate School of Biological Sciences, Mount Sinai trains biomedical researchers with an emphasis on the rapid translation of discoveries of basic research into new techniques for fighting disease. One indication of Mount Sinai’s leadership in scientific investigation is its receipt during fiscal year 2004 of $153.2 million. Mount Sinai now ranks 25th among the nation’s medical schools in receipt of research support from NIH. Mount Sinai School of Medicine also is known for unique educational programs such as the Humanities in Medicine program, which creates opportunities for liberal arts students to pursue medical school, and instructional innovations like The Morchand Center, the nation’s largest program teaching students and physicians with "standardized patients" to become not only highly skilled, but compassionate caregivers. Long dedicated to improving its community, the School extends its boundaries to work with East Harlem and surrounding communities to provide access to health care and educational programs to at risk populations.

| EurekAlert!
Further information:
http://www.mssm.edu
http://www.walkstudy.com

More articles from Health and Medicine:

nachricht Laser activated gold pyramids could deliver drugs, DNA into cells without harm
24.03.2017 | Harvard John A. Paulson School of Engineering and Applied Sciences

nachricht What does congenital Zika syndrome look like?
24.03.2017 | University of California - San Diego

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>